BEDFORD, Mass.--(BUSINESS WIRE)--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
-
Stifel 2016 Healthcare Conference
Tuesday, November 15, 2016 at 10:15 a.m. Eastern Time
Lotte New York Palace Hotel, New York, NY
-
Piper Jaffray 28th Annual Healthcare
Conference
Wednesday, November 30, 2016 at 3:30 p.m. Eastern Time
Lotte New York Palace Hotel, New York, NY
Live audio webcasts of the presentations can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
(NASDAQ: OCUL) is a biopharmaceutical company focused on the development
and commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix has submitted an NDA for post-surgical
pain for its lead product candidate, DEXTENZA™ (dexamethasone insert),
which is in Phase 3 clinical development for post-surgical ocular
inflammation and pain and allergic conjunctivitis. OTX-TP (travoprost
insert) is in Phase 3 clinical development for glaucoma and ocular
hypertension. Ocular Therapeutix is also evaluating injectable drug
delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery. For additional information about the
Company, please visit www.ocutx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161109005107/en/
